---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-262519"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:52:37.186280+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xenon Q3 net loss $90.9M, Phase 3 FOS study fully enrolled, new CFO appointed

## Summary
- Net loss $90.9M (vs $62.8M Q3 2024) on higher R&D spend; R&D expenses $77.1M (vs $57.0M).
- Phase 3 X-TOLE2 FOS study completed enrollment (380 patients); topline data expected early 2026.
- Phase 3 MDD (X-NOVA2/3) and BPD (X-CEED) studies continue recruiting; Phase 1 Nav1.7 and Kv7 studies underway.
- Tucker Kelly appointed CFO to lead finance strategy ahead of azetukalner launch.
- Cash $555.3M as of Sept 30, 2025; runway into 2027.

## SEC filing metadata
- accession: 0001193125-25-262519
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000119312525262519/0001193125-25-262519-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000119312525262519/xene-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-262519
- JSON: https://secwatch.observer/filing/0001193125-25-262519.json
- Plain text: https://secwatch.observer/filing/0001193125-25-262519.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.